



UNICHEM
LABORATORIES LTD.

Fax No : 91 (22) 2678 4391 / 5198
Tel. No. : 91 (22) 66888333
Website : <http://www.unichemlabs.com>
CIN : L99999MH1962PLC012451.

Registered & Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

December 14, 2017

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051

(BSE Scrip Code: 506690)

(NSE Scrip Code: UNICHEMLAB)

Dear Sir,

Sub: Unichem Laboratories Ltd., completes the sale and transfer of the Company's domestic formulations business in India and Nepal to Torrent Pharmaceuticals Limited

We refer to our letter dated November 3, 2017 on the above subject. Unichem Laboratories Limited ("Unichem") has completed the sale and transfer of its domestic formulations business in India and Nepal together with the manufacturing facility at Sikkim, on a going concern basis by way of slump sale, to Torrent Pharmaceuticals Limited (TPL). This transaction was in pursuance of the definitive binding agreement entered into between Unichem and TPL on 3rd November, 2017.

Please find enclosed a press release for the same.

Kindly take note of the above.

Thanking you,

Yours Sincerely,

For Unichem Laboratories Ltd.,

NeemaThakore
Head – Legal & Company Secretary

Encl.: A/a



UNICHEM
LABORATORIES LTD.

Unichem Bhavan
Prabhat Estate, Off S.V.Road,
Jogeshwari (West),
Mumbai - 400 102.
CIN: L99999MH1962PLC01245 I

Tel. No: +91 (22) 66 888 333

Fax. No: +91 (22) 267 843 91/ 5198

PRESS RELEASE

Unichem Laboratories Limited ("Unichem") has completed the sale and transfer of its domestic formulations business in India and Nepal, on a going concern basis by way of slump sale, to Torrent Pharmaceuticals Limited (TPL).

Going ahead Unichem will:

- focus attention on all aspects of the international business including finished formulations, API, contract manufacturing and contract research;
- increase its investments in R&D in the New Chemical and Biological Entities (NCE & NBE), Bio-similars and complex generics; and
- reward shareholders

Mr. Jayendra Shah, played a pivotal role in successful consummation of the transaction. He was the sole financial advisor to Unichem on negotiations, valuations and deal closure. N A Shah Associates LLP, Chartered Accountants were the advisors for tax and related matters and Trans Continental Capital Advisors Pvt. Ltd. were the strategic advisors.

About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. The Company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at www.unichemlabs.com

For more information please contact:

Ms. Neema Thakore
Ph: +91-22-66888 404
E-mail: neema.thakore@unichemlabs.com

Mr. Rakesh Parikh
Ph: +91-22-66888 414
E-mail: rparikh@unichemlabs.com

Disclaimer: This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.